Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in ARM’s Cell and Gene Meeting on the Med 2026, taking place 28 – 30 April 2026, in Rome, Italy.
Anita van der Meer, Head of Business Development and Partnerships at VVMF, will be available to discuss the organisation’s expertise across research, process and analytical development, GMP viral vector manufacturing, and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.
As Australia’s only viral vector Contract Development and Manufacturing Organisation (CDMO) providing complete life cycle services to the global cell and gene therapy (CGT) sector, VVMF delivers high-quality lentiviral (LV) and adeno-associated viral (AAV) vector solutions tailored to their research, clinical, and commercial needs.
Backed by leading scientific and clinical expertise, VVMF provides a compelling strategic advantage – further strengthened by Australia’s 43.5% R&D tax incentive, which provides a rebate of up to 43.5% for eligible companies.
Commenting on VVMF’s participation, Anita van der Meer said
“With its strong international focus, ARM’s Cell & Gene Meeting on the Med provides an ideal platform to engage with innovators shaping the future of cell and gene therapy. I look forward to discussing how VVMF’s capabilities, and the Australia Advantage, can support the progression of advanced therapies.”
To schedule a meeting, connect via the meeting’s PartneringONETM platform or contact info@vvmf.com.au
Unlocking the future of medicine – through strong connections built at ARM’s Cell and Gene Meeting on the Med.